NDAORALSOLUTION
Approved
Nov 2014
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OBREDON is an oral solution combining guaifenesin (an expectorant) and hydrocodone bitartrate (an opioid cough suppressant) indicated for cough and congestion relief. This fixed-dose combination targets patients requiring both mucus clearance and cough suppression via central nervous system depression and mucolytic action.
Peak9.5 years to LOE
Product is in peak commercial stage with stable market position; brand team likely operating at steady-state with maintenance-focused commercial strategy and moderate headcount.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OBREDON offers stable, mature-market experience in a peak-lifecycle, controlled-substance product with long patent protection. Roles emphasize commercial execution, compliance, and stakeholder management rather than innovation—ideal for professionals seeking predictable career progression in established brands.
Brand ManagerField Sales Representative
Worked on OBREDON at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.